Given the availability of effective therapies that exploit defects in homologous recombination, such as PARP-1 inhibitors and cisplatin, it is increasingly important to determine whether these therapies are likely to be effective in ER+BRCA1-mutant cancers. This evidence concerns the gene PARP1 and cancer.